Remote Monitored Systems PLC Board appointments (7935V)
April 19 2021 - 1:00AM
UK Regulatory
TIDMRMS
RNS Number : 7935V
Remote Monitored Systems PLC
19 April 2021
19 April 2021
Remote Monitored Systems plc
("RMS" or the "Company")
Board appointments
Further to the announcement of 18 February 2021, the Company is
pleased to announce the appointments of Dr Gareth Cave and Dr
Felicity Sartain as non-executive directors of the Company,
effective immediately. Dr Felicity Sartain will be an independent
non-executive director.
Dr Gareth Cave is a founder and Chairman of Pharm2Farm Ltd
("P2F"), the Company's wholly owned subsidiary. Dr Cave gained his
BSc, MSc and PhD in Chemistry from the University of Warwick. He
subsequently co-established the Australian Centre for Green
Chemistry at Monash University in Australia, whilst also pioneering
a new "green" solvent-free chemical reaction process, that later
led to the two patents licenced to P2F to manufacture and
fictionalise their nanotechnology processes. Dr Cave later went on
to work as an academic at the Universities of Leeds, Liverpool and
University of Missouri, USA before returning to the UK at
Nottingham Trent University in 2005 where he is currently Head of
Inorganic Chemistry. His current interdisciplinary university
research group, of 11 PhD's utilise nanotechnology across a
plethora of applications from cancer immunology, and treatments of
Alzheimer's through to food security - both plant and
livestock.
Dr Felicity Sartain has a multi-disciplinary background
established over 10 years including managerial, commercial and
research in the Healthcare, Life Science and Nanotechnology
sectors. She holds a PhD in Biotechnology from the University of
Cambridge and an MSc in Chemistry at the University of York. She
has also undertaken Post-Doctoral Research at the University of
Cambridge following an industrial placement with GlaxoSmithKline.
Felicity is currently Chief Operating Officer of Closed Loop
Medicine where she initially worked as a consultant from September
2017.
Antony Legge, Executive Chairman of RMS, said:
" We are delighted to welcome both Gareth and Felicity to the
Board. They are both highly accomplished in their fields with deep
knowledge and experience in nanotechnology. The appointments
strengthen and extend the Board's skill set, and we very much look
forward to benefitting over the coming years as their contributions
support RMS's growth trajectory."
The following disclosures are required regarding Drs Cave and
Sartain's appointment to the RMS Board pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies ("AIM Rules"):
Full name: Dr Gareth Wynn Vaughan Cave
Age: 46
Current directorships/partnerships: Pharm2Farm Ltd
Former directorships/partnerships in the last 5 years: N/A
Dr. Cave currently holds 289,645,185 ordinary shares in the
Company, representing 13.9% of the Company's total issued share
capital.
Full name: Dr Felicity Kate Sartain
Age: 41
Current directorships/partnerships: Profiscio Ltd
Previous directorships/partnerships in the last five years: NanoScientium Ltd
Save as set out above, there is no further information to be
disclosed in respect of Dr Gareth Cave and Dr Felicity Sartain
under Schedule 2(g) of the AIM Rules.
- ENDS -
ENQUIRIES :
Remote Monitored Systems plc via IFC Advisory
Antony Legge (Executive Chairman)
SP Angel Corporate Finance LLP +44 20 3470 0470
Nominated Adviser and Joint Broker
Stuart Gledhill
Caroline Rowe
Peterhouse Capital Limited +44 20 7469 0930
Joint Broker
Lucy Williams
IFC Advisory Ltd +44 20 3934 6630
Graham Herring
Zach Cohen
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAGPUCACUPGGAQ
(END) Dow Jones Newswires
April 19, 2021 02:00 ET (06:00 GMT)
Nanosynth (LSE:NNN)
Historical Stock Chart
From Apr 2024 to May 2024
Nanosynth (LSE:NNN)
Historical Stock Chart
From May 2023 to May 2024